Title: Accelerated Innovative Process Chemistry Applications are Integral Part of Drug Development
Dr. Chris H. Senanayake, Vice President, Boehringer Ingelheim Pharmaceuticals, Inc., USA |
||
Title: Overview of Biosimilar Develpment
Dr. Steffen Nock, Senior Vice President and Global Head of Biologics, Teva Pharmaceuticals, USA |
||
Title: Understanding and Overcoming Barriers in RNA Interference Dr. Bruce Given, COO, Arrowhead Research Corporation, USA |
||
|
Title: Precision PharmacologyBenchtop to Bedside: Thinking inside Precision Medicine via Diseases-Specific Chemogenomics Knowledgebases and TargetHunter© Dr. Xiang-Qun Xie, Associate Dean for Research Innovation and Professor of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, USA |
|
|
Title: Disaccharide Mimetics as Drugs Against Cancer and Epitopes for Anti-Cancer Vaccine Candidates Dr. Pierre Vogel, Professor, Swiss Institute of Technology in Lausanne (EPFL), Switzerland |
|
|
Keynote Speech Title: New Flexible Methods for Signal Detection in Pharmacovigillance Dr. Michal Abrahamowicz, James McGill Professor, McGill University, Canada |
|
|
Title: The Crucial Role Process Equipment Plays in Drug Product Safety and Risk Dr. Tamara Fridman, CEO, Vanasyl LLC., USA |
|
|
Title: ViscoGel™ and Viscomulsion™, Two Novel Particulate Hydrogel Drug Delivery Systems Allowing for Tuning of Drug Release- and Biodegradation Rate Dr. Mats Andersson, Founder and Chief Scientific Officer, Viscogel AB, Sweden |
|
|
Title: Taste Masking Evaluation Using Simulated Saliva for Polymer Coated API in Pediatric Formulation Development Dr. Xujin Lu, Sr. Principal Scientist, Bristol-Myers Squibb Company, USA |
|
|
Title: Human Monoclonal Antibodies as Candidate Therapeutics Against Cancer and Viruses Dr. Dimiter S. Dimitrov, Head, National Cancer Institute, NIH, USA |
|
|
Title: Developability and Early Risk Assessment in Antibody and Biopharmaceutical Development: Towards a Holistic QbD Implementation Dr. Jesus Zurdo, Senior Director, Lonza Pharma & Biotech, UK |
|
|
Title: A Revolutionary Strategy for Cancer Therapy: The Cancer Targeting Gene-Viro-Therapy Dr. Xinyuan Liu, Professor, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, China |
|
|
Title: Risk Mitigation Strategies in the Sale and Distribution of Generic Pharmaceutical Products in the U.S. Market Dr. Joseph P. Thomas, Chair of the Life Sciences Group and Co-chair of the Litigation Department, Ulmer & Berne LLP, USA |
| |